⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

PBI-4050 (pbi-4050) | 加速させる、線維化研究を

Home/Drugs/PBI-4050

PBI-4050

pbi-4050

Phase 2b

Sponsor: Liminal BioSciences

Indication: IPF

Mechanism of Action

GPR40 agonist / GPR84 antagonist

Target: GPR40, GPR84

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT03637049

Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects

Phase:PHASE1Org:Liminal BioSciences Ltd.

TERMINATED

Relevant Publications (PubMed)

No recent publications found for pbi-4050.

Validated Models

This drug has been validated in the following preclinical models:

NCT05349435

A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate

Phase:PHASE1Org:Liminal BioSciences Ltd.

TERMINATEDNCT02955888

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Phase:PHASE2Org:Liminal BioSciences Ltd.

TERMINATEDNCT03081598

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Phase:PHASE2Org:Liminal BioSciences Ltd.

COMPLETEDNCT04695041

A Healthy Volunteer Study of PBI-4050

Phase:PHASE1Org:Liminal BioSciences Ltd.

View all trials on ClinicalTrials.gov